Dec 21, 2012 by Brenton Flynn and Dave WilliamsonIs Intuitive Surgical Really in Trouble?The shorts have their concerns about Intuitive Surgical, surprisingly, but are these worries valid?
Dec 20, 2012 by Brenton Flynn and Dave WilliamsonIntuitive Shareholders, Stop Panicking!Citron research has called for a steep dropoff in Intuitive Surgical's share price. Does that mean it's time to panic?
Dec 20, 2012 by Brenton Flynn and Dave WilliamsonIs AbbVie the Next AstraZeneca?Astrazeneca is facing a couple very steep patent cliffs. Will Abbott Labs' new spinoff be next?
Dec 19, 2012 by Brenton Flynn, Dave Williamson, and Max MacalusoEmerging Markets Health Care -- A Unique ChallengeIn this part of our roundtable discussion, how JNJ could see some growth in its medical devices sector, if it could tap the difficult emerging markets.
Dec 17, 2012 by Brenton Flynn, Dave Williamson, and Max MacalusoShould Johnson & Johnson Split Up?A lot of companies in the medical sector have been spinning off divisions recently. Would that be a good move for conglomerate Johnson & Johnson too?
Dec 14, 2012 by Brenton FlynnAre These Drugs Destined to Fail Again?Are these pharma companies setting themselves up for failure?
Dec 14, 2012 by Brenton FlynnIs This Really the Next Obesity Drug?Already a blockbuster, this drug may now may be joining the obesity space.
Dec 14, 2012 by Brenton FlynnEli Lilly: If at First You Don't Succeed...Eli Lilly's drug Solanezumab has already seen failure in the Alzheimer's disease space, but the company is giving it another go.
Dec 14, 2012 by Brenton FlynnThe Best of 2012: Arena PharmaceuticalsArena Pharmaceuticals and its FDA approved obesity drug are up 374% YTD, making this company #4 on our list of the very best healthcare stocks of 2012.
Dec 14, 2012 by Brenton FlynnBig News for This Blockbuster DrugJohnson & Johnson got the good news it was waiting for.
Dec 14, 2012 by Brenton FlynnThe Best of 2012: SareptaSarepta's tremendous advances in the treatment of Duchenne muscular dystrophy have brought the stock up 556% this year, and earned it the title of the #1 best stock in the healthcare sector for 2012.
Dec 14, 2012 by Brenton Flynn and Dave WilliamsonWhy This Pharma Stock Tanked YesterdayRigel Pharmaceutical took a huge dive today. What happened?
Dec 14, 2012 by Brenton FlynnWhy This Pharma Stock Tanked YesterdayRigel Pharmaceutical took a huge dive today. What happened?
Dec 13, 2012 by Brenton FlynnThe Best of 2012: ACADIA PharmaceuticalsExcitement over positive results around its drug for Parkinson's disease psychosis has propelled this stock up 380% for the year. That makes this company #3 on our list of the very best healthcare stocks of 2012.
Dec 13, 2012 by Brenton FlynnThe Best of 2012: BioDelivery SciencesBioDelivery Sciences' platform for delivering drugs through the mucous membrane of the inner cheek has certainly stirred investor interest, as the stock is up 428% for the year. That makes it #2 on our list of the best of the best this year in healthcare.
Dec 11, 2012 by Brenton Flynn and Max MacalusoThe Best of 2012: OrexigenOrexigen, a major player in the obesity space at the moment, is now up 230% for the year, landing the company at No. 17 on our list of the healthcare stocks that have been the very best for investors in 2012.
Dec 11, 2012 by Brenton Flynn and Max MacalusoThe Best of 2012: SantarusSantarus is profitable from its commercialized diabetes and high cholesterol drugs, has some exciting things in the pipeline, and is up over 200% this year, putting it at #16 on our list of the best healthcare stocks of 2012.
Dec 11, 2012 by Brenton Flynn and Max MacalusoThe Best of 2012: Infinity PharmaceuticalsInfinity Pharmaceuticals' exciting pipeline alone has been enough to drive investor buzz, and drive share prices up for the company over 200% for the year. It comes in at #18 on our list of the best healthcare stocks for investors in 2012.
Dec 11, 2012 by Brenton Flynn and Max MacalusoThe Best of 2012: BioMimeticThe announcement that BioMimetic is being acquired by Wright Medical has contributed to BioMimetic shares being up 167% this year, leaving it at No. 19 on our list of the best healthcare stocks of 2012.
